argenx reports third quarter 2019 financial results and provides business update
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
Enrollment on track for Phase 3 ADAPT trial of efgartigimod in gMG patients with topline results expected in 2H20Two efgartigimod trial initiations expected in 4Q19: Phase 2 proof-of-concept trial in CIDP patients and Phase 3 ADVANCE trial in primary ITP patientsData from Phase 1 HV trial of ENHANZE® SC formulation of efgartigimod expected by YE19 October 24, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its financial results for the third quarter ended September 30, 2019 and provided a business update. “We have had another strong quarter of execution across our development pipeline and look forward to a busy remainder of the year that should set the stage for an exciting 2020. With efgartigimod, we are planning for three upcoming read
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) had its price target lowered by analysts at JPMorgan Chase & Co. from $560.00 to $500.00. They now have an "overweight" rating on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) had its price target lowered by analysts at HC Wainwright from $451.00 to $448.00. They now have a "buy" rating on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) had its price target lowered by analysts at JMP Securities from $471.00 to $468.00. They now have a "market outperform" rating on the stock.MarketBeat
- argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- argenx announces results of Annual General Meeting of ShareholdersGlobeNewswire
ARGX
Earnings
- 5/9/24 - Miss
ARGX
Sec Filings
- 5/9/24 - Form 6-K
- 5/8/24 - Form 6-K
- 4/16/24 - Form 6-K
- ARGX's page on the SEC website